3D0A Stock Overview
A biotech company, engages in the development and commercialization of predictive technological products to personalize treatment plans for patients with specific Telo Genomics Corp., a molecular diagnostics company, engages in the development and commercialization of predictive technological products to personalize treatment plans for patients with specific conditions.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Telo Genomics Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.11 |
| 52 Week High | CA$0.18 |
| 52 Week Low | CA$0.035 |
| Beta | 1.19 |
| 11 Month Change | 19.57% |
| 3 Month Change | 96.43% |
| 1 Year Change | -37.14% |
| 33 Year Change | -66.26% |
| 5 Year Change | 20.22% |
| Change since IPO | -93.94% |
Recent News & Updates
Recent updates
Shareholder Returns
| 3D0A | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -9.8% | 0.6% | 0.09% |
| 1Y | -37.1% | -18.6% | 3.1% |
Return vs Industry: 3D0A underperformed the German Biotechs industry which returned -18.6% over the past year.
Return vs Market: 3D0A underperformed the German Market which returned 3.1% over the past year.
Price Volatility
| 3D0A volatility | |
|---|---|
| 3D0A Average Weekly Movement | 45.7% |
| Biotechs Industry Average Movement | 6.3% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.7% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 3D0A's share price has been volatile over the past 3 months.
Volatility Over Time: 3D0A's weekly volatility has increased from 32% to 46% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | Sabine Mai | www.telodx.com |
Telo Genomics Corp., a biotech company, engages in the development and commercialization of predictive technological products to personalize treatment plans for patients with specific Telo Genomics Corp., a molecular diagnostics company, engages in the development and commercialization of predictive technological products to personalize treatment plans for patients with specific conditions. It provides TeloView-SMM application; TeloView, an analysis software platform for prediction of genomic instability. It has a collaboration agreement with the Mayo Clinic to validate its SMM tests for multiple myeloma.
Telo Genomics Corp. Fundamentals Summary
| 3D0A fundamental statistics | |
|---|---|
| Market cap | €9.97m |
| Earnings (TTM) | -€2.03m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-4.4x
P/E RatioIs 3D0A overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 3D0A income statement (TTM) | |
|---|---|
| Revenue | CA$0 |
| Cost of Revenue | CA$0 |
| Gross Profit | CA$0 |
| Other Expenses | CA$2.97m |
| Earnings | -CA$2.97m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.042 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 3D0A perform over the long term?
See historical performance and comparison